ATE355841T1 - Verwendung von pyrazolo ( 3,4-b) pyridin als cyclin-abhängige kinase hemmer - Google Patents

Verwendung von pyrazolo ( 3,4-b) pyridin als cyclin-abhängige kinase hemmer

Info

Publication number
ATE355841T1
ATE355841T1 AT98960781T AT98960781T ATE355841T1 AT E355841 T1 ATE355841 T1 AT E355841T1 AT 98960781 T AT98960781 T AT 98960781T AT 98960781 T AT98960781 T AT 98960781T AT E355841 T1 ATE355841 T1 AT E355841T1
Authority
AT
Austria
Prior art keywords
cycline
pyrazolo
pyridine
kinase inhibitor
dependent kinase
Prior art date
Application number
AT98960781T
Other languages
English (en)
Inventor
Raj N Misra
S David Kimball
David B Rawlins
Kevin R Webster
Isia Bursuker
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE355841T1 publication Critical patent/ATE355841T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT98960781T 1997-12-13 1998-12-07 Verwendung von pyrazolo ( 3,4-b) pyridin als cyclin-abhängige kinase hemmer ATE355841T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6963397P 1997-12-13 1997-12-13

Publications (1)

Publication Number Publication Date
ATE355841T1 true ATE355841T1 (de) 2007-03-15

Family

ID=22090219

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98960781T ATE355841T1 (de) 1997-12-13 1998-12-07 Verwendung von pyrazolo ( 3,4-b) pyridin als cyclin-abhängige kinase hemmer

Country Status (11)

Country Link
US (1) US6107305A (de)
EP (1) EP1043998B1 (de)
JP (1) JP2002508324A (de)
AR (1) AR017852A1 (de)
AT (1) ATE355841T1 (de)
AU (1) AU747705C (de)
CA (1) CA2314355A1 (de)
DE (1) DE69837282T2 (de)
ES (1) ES2281941T3 (de)
WO (1) WO1999030710A1 (de)
ZA (1) ZA9811178B (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039007A1 (en) * 1997-03-03 1998-09-11 Board Of Regents, The University Of Texas System Supression of cyclin kinase 2 activity for prevention and treatment of dna viral infections
US6407103B2 (en) 1998-04-21 2002-06-18 Bristol-Myers Squibb Pharma Company Indeno [1,2-c] pyrazol-4-ones and their uses
US6326379B1 (en) * 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
US6291504B1 (en) 1999-10-20 2001-09-18 Dupont Pharmaceuticals Company Acylsemicarbazides and their uses
US20040048844A1 (en) * 1999-10-20 2004-03-11 Bristol-Myers Squibb Pharma Company Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents
FR2806626B1 (fr) * 2000-03-22 2003-11-28 Centre Nat Rech Scient Utilisation de substances modulatrices de l'expression ou de la fonction d'une proteine impliquee dans le cycle cellulaire pour le traitement ou la prevention des lesions neurales aigues
EP1278749B1 (de) 2000-04-25 2005-01-26 Bristol-Myers Squibb Company Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer
WO2001082967A1 (fr) * 2000-04-28 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Compositions medicinales destinees a supprimer la production de ?-amyloide
KR100423899B1 (ko) * 2000-05-10 2004-03-24 주식회사 엘지생명과학 세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸
ATE295354T1 (de) 2000-08-18 2005-05-15 Agouron Pharma Heterozyklische-hydroximino-fluorene und ihre verwendung zur inhibierung von proteinkinasen
PE20020394A1 (es) * 2000-08-18 2002-06-21 Agouron Pharma Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2
WO2002030410A2 (en) * 2000-10-10 2002-04-18 Board Of Regents, The University Of Texas System Suppression of cyclin kinase activity for prevention and treatment of infections
WO2002044174A2 (en) * 2000-12-01 2002-06-06 Bristol-Myers Squibb Pharma Company 3-(2,4-dimethylthiazol-5-yl) indeno[1,2-c]pyrazol-4-one derivatives as cdk inhibitors
US6849631B2 (en) 2000-12-08 2005-02-01 Bristol Myers Squibb Pharma Company Semicarbazides and their uses
US6977262B2 (en) * 2001-02-02 2005-12-20 Mitsubishi Pharma Corporation Dihydropyrazolopyridine compounds and pharmaceutical use thereof
AU2002342878A1 (en) * 2001-05-16 2002-11-25 Axxima Pharmaceuticals Ag Pyridylpyrimidine derivatives as effective compounds against prion diseases
JP3896309B2 (ja) * 2001-07-09 2007-03-22 ファイザー株式会社 プロテインキナーゼｃ阻害物質としてのピラゾロキノリノン誘導体
EP1435947B1 (de) 2001-10-19 2007-08-15 Ortho-McNeil Pharmaceutical, Inc. 2-phenyl benzimidazole und imidazo-¬4,5|-pyridine als cds1/chk2-inhibitoren und adjuvantien in der chemotherapie oder strahlungstherapie zur behandlung von krebs
US8748475B2 (en) 2004-01-12 2014-06-10 Natrogen Therapeutics International, Inc. Methods and compositions for treating lupus
US20100098702A1 (en) 2008-09-16 2010-04-22 Longgui Wang Method of treating androgen independent prostate cancer
US20050154046A1 (en) * 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
US7582670B2 (en) 2001-12-13 2009-09-01 Natrogen Therapeutics, Inc. Methods of treating an inflammatory-related disease
GB0218625D0 (en) * 2002-08-10 2002-09-18 Astex Technology Ltd Pharmaceutical compounds
CN100376580C (zh) * 2002-09-04 2008-03-26 先灵公司 作为细胞周期蛋白依赖性激酶抑制剂的吡唑并嘧啶
US8673924B2 (en) * 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US7196078B2 (en) * 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2004022561A1 (en) * 2002-09-04 2004-03-18 Schering Corporation Pyrazolopyrimidines as cyclin-dependent kinase inhibitors
US7119200B2 (en) * 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7161003B1 (en) * 2002-09-04 2007-01-09 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US8580782B2 (en) * 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
PT1537116E (pt) * 2002-09-04 2010-09-03 Schering Corp Pirazolopirimidinas adequadas para o tratamento de doenças cancerosas
AR041292A1 (es) * 2002-09-19 2005-05-11 Schering Corp Pirazolopiridinas como inhibidores de quinasa dependientes de ciclina
KR101312736B1 (ko) 2003-02-27 2013-09-27 팔라우 파르마 에스에이 피라졸로피리딘 유도체
JP4726235B2 (ja) 2003-04-17 2011-07-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 癌の処置のためのチェックポイントキナーゼｃｄｓ１（ｃｈｋ２）インヒビターとしての２−フェニル−ベンズイミダゾールおよび２−フェニル−イミダゾ−‘４，５！−ピリジン誘導体
FR2857363B1 (fr) * 2003-07-10 2007-09-07 Aventis Pharma Sa 4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c] pyridines substituees compositions les contenant et utilisation
AR045037A1 (es) * 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
US7405220B2 (en) * 2004-06-09 2008-07-29 Hoffmann-La Roche Inc. Pyrazolopyrimidines
EP2298291A3 (de) 2004-06-18 2011-08-03 Agennix USA Inc. Kinasehemmer zur Behandlung von Krebs
EP1674457B1 (de) 2004-12-23 2009-06-03 GPC Biotech AG Quadratsäurederivate mit antiproliferativer Wirkung
RS50821B (sr) 2005-06-27 2010-08-31 Sanofi-Aventis Derivati pirazolopiridina kao inhibitori beta-adrenergičnog receptora kinaze 1
DE602005018911D1 (de) * 2005-07-20 2010-03-04 Aventis Pharma Sa 1,4-Dihydropyridine-kondensierte Heterocyclen Verfahren zu deren Herstellung sowie Verwendung und Zusammensetzungen dergleichen
CA2621983A1 (en) * 2005-09-09 2007-03-22 Schering Corporation Azafused cyclin dependent kinase inhibitors
CN101321760A (zh) 2005-10-06 2008-12-10 先灵公司 作为蛋白激酶抑制剂的吡唑并嘧啶
TW200804386A (en) * 2005-11-10 2008-01-16 Schering Corp Imidazopyrazines as protein kinase inhibitors
US7705009B2 (en) * 2005-11-22 2010-04-27 Hoffman-La Roche Inc. 4-aminopyrimidine-5-thione derivatives
BRPI0708615A2 (pt) 2006-03-07 2011-06-07 Array Biopharma Inc compostos de pirazol heterobicìclicos e métodos de uso
US20090175852A1 (en) 2006-06-06 2009-07-09 Schering Corporation Imidazopyrazines as protein kinase inhibitors
EP1914234A1 (de) * 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidinen und ihre Verwendung als kinase Inhibitoren
MX2009004785A (es) * 2006-10-31 2009-06-05 Schering Corp Amidas 2-aminotiazol-4-carboxilicas como inhibidores de proteina quinasa.
CA2668210C (en) 2006-10-31 2013-03-12 Schering Corporation Anilinopiperazine derivatives and methods of use thereof
AR063531A1 (es) * 2006-10-31 2009-01-28 Schering Corp Derivados de anilinopiperazina y composicion farmaceutica
US8450348B2 (en) * 2007-02-21 2013-05-28 Forma Tm, Llc Derivatives of squaric acid with anti-proliferative activity
EP2409700A1 (de) 2007-05-08 2012-01-25 Schering Corporation Verfahren zur Behandlung mit intravenösen Formulierungen mit Temozolomid
JP2011513331A (ja) 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド ピラゾール［３，４−ｂ］ピリジンＲＡＦ阻害剤
EP2112150B1 (de) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Verbesserte Raf-Inhibitoren
EP2112152A1 (de) 2008-04-22 2009-10-28 GPC Biotech AG Dihydropteridinones als Plk-Inhibitoren
WO2011000566A2 (en) * 2009-06-30 2011-01-06 Savira Pharmaceuticals Gmbh Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections
WO2011025706A2 (en) 2009-08-26 2011-03-03 Schering Corporation Heterocyclic amide compounds as protein kinase inhibitors
EP2325185A1 (de) 2009-10-28 2011-05-25 GPC Biotech AG Plk-Inhibitor
HU0900798D0 (en) 2009-12-21 2010-03-01 Vichem Chemie Kutato Kft 4-phenylamino-pyrimidine derivatives having protein kinase inhibitor activity
RU2011122942A (ru) 2011-06-08 2012-12-20 Общество С Ограниченной Ответственностью "Асинэкс Медхим" Новые ингибиторы киназ
WO2013148775A1 (en) 2012-03-30 2013-10-03 Merck Sharp & Dohme Corp. Predictive biomarker useful for cancer therapy mediated by a cdk inhibitor
CN106573932B (zh) * 2014-08-22 2019-07-30 默克专利股份公司 吲唑类
JP2022524887A (ja) 2019-03-22 2022-05-10 ドイチェス クレブスフォルシュングスツェントルム ヒストンデアセチラーゼ１０の新規の阻害剤
EP3712127A1 (de) 2019-03-22 2020-09-23 Deutsches Krebsforschungszentrum Neuartige inhibitoren der histon-deacetylase 10

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1923990C3 (de) * 1969-05-10 1978-11-23 Bayer Ag Verfahren zur Herstellung von N-substituierten M-Dihydropyridin-S.S-dicarbonsäureestern
BE787249A (fr) * 1971-08-05 1973-02-05 Squibb & Sons Inc Derives amino d'acides pyrazolopyridine carboxyliques, leurs esters et les sels de ces composes, ainsi que leurs procedes de preparation
US3810905A (en) * 1971-11-04 1974-05-14 Squibb & Sons Inc Pyrazolo(3,4-b)pyridine-5-carboxamides
US3773778A (en) * 1972-01-24 1973-11-20 Squibb & Sons Inc Sulfur derivatives of pyrazolo (3,4-b)pyridines
US3987051A (en) * 1975-04-16 1976-10-19 E. R. Squibb & Sons, Inc. Method for producing 1-unsubstituted pyrazolo[3,4-b]pyridine ketones
US3985757A (en) * 1975-09-17 1976-10-12 E. R. Squibb & Sons, Inc. Pyrazolopyridine ketones
US4552883A (en) * 1982-06-15 1985-11-12 Ici Americas Inc. Pyrazolo[3,4-b]pyridine carboxylic acid esters and their pharmaceutical use
US5733920A (en) * 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases

Also Published As

Publication number Publication date
EP1043998B1 (de) 2007-03-07
ES2281941T3 (es) 2007-10-01
EP1043998A4 (de) 2004-02-04
AU1629799A (en) 1999-07-05
CA2314355A1 (en) 1999-06-24
JP2002508324A (ja) 2002-03-19
US6107305A (en) 2000-08-22
EP1043998A1 (de) 2000-10-18
AU747705B2 (en) 2002-05-23
AR017852A1 (es) 2001-10-24
WO1999030710A1 (en) 1999-06-24
DE69837282T2 (de) 2007-11-08
DE69837282D1 (de) 2007-04-19
AU747705C (en) 2004-09-23
ZA9811178B (en) 2000-06-07

Similar Documents

Publication Publication Date Title
ATE355841T1 (de) Verwendung von pyrazolo ( 3,4-b) pyridin als cyclin-abhängige kinase hemmer
FI944305L (fi) Pyrido(2,3-d)pyrimidiinijohdannaiset fosfodiesteraasi-inhibiittoreina
ATE257157T1 (de) Pyrrolo(2,3-d)pyrimidin-verbindungen als protein kinasen hemmer
TR199801367A3 (tr) 5H- tiazol (3,2-a) pirimidin türevleri
FI962155L (fi) Uudet 9-hydroksipyrido (1,2-a) pyrimidin-4-onieetterijohdannaiset
IS5197A (is) Nikótínamíð afleiður
DE69431880D1 (de) Verwendung von (2-imidazolin-2-yl-amino) quinoxalinderivaten
ID23889A (id) Turunan-turunan piridina
ATE229955T1 (de) Substituierte 1,8-naphthyridin-4(1h)-one als phosphodiesterase 4-inhibitoren
DE69529777D1 (de) 2-Benzylthio-8-amino(1,2,4)triazolo(1,5-a)pyridine
DE69232976D1 (de) Heteroarylamine als neue acetylcholinesterase-inhibitoren
FI961564L (fi) Imidatso(1,2-a)pyridiinien alkoksialkyylikarbamaatit
NO985684L (no) 1,3,8-Triaza-spiro(4,5)dekan-4-on-derivater
DE59009117D1 (de) [1,2,4] Triazolo [1,5-a]pyridine.
DE69626416D1 (de) Salze von chinolinderivaten als nk3 antagonisten
ATE50259T1 (de) 1,6-naphthyridin-2(1h)-one brauchbar als kardiotonika.
DE69104481D1 (de) Imidazo[4,5-c]pyridine als paf antagonisten.
EP0417760A3 (en) Phenylalkanoyl substituted imidazo(4,5-c) pyridines
DE58907412D1 (de) Neue substituierte Pyrido(2,3-d)pyrimidine.
FI954614L (fi) Imidatsolokinoksalinonijohdannaiset EAA-antagonisteina
DE59100220D1 (de) Verwendung von kupfersalzen als kristallisationsinhibitoren.
FI955829L (fi) Heterosyklinen kemia
MX9500228A (es) N-oxidos de 4-arilpiperazinas y 4-arilpiperidinas.
ATE255401T1 (de) Färbemittel enthaltend pyrazolo(1,5- a)pyrimidinderivate als oxidationsmittel und pyridinderivate als kuppler sowie färbeverfahren
GB2264115B (en) 1H-2-Methylimidazo(4,5-c)pyridinyl Derivatives as PAF Antagonists

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1043998

Country of ref document: EP

REN Ceased due to non-payment of the annual fee